A multiomic analysis led by the IrsiCaixa AIDS Research Institute has uncovered genetic and immune mechanisms in some ...

Gilead has grown to become a leader in the fight against HIV and has announced efforts to improve access to a new, highly ...

PrEP use increased between 2013 and 2023, according to a research letter published online in the Journal of the American Medical Association.

Some people infected with HIV are teeming with virus, but don’t get sick. Their resistive powers probably come from a mix of ...

A traveller who hopped into his hotel bed only to feel a sudden 'prick' sensation was left panicked after realising what it ...

Long-acting injectable PrEP is now to be covered without cost-sharing under Affordable Care Act rules, the Biden ...

With just 15 days until the presidential election, the federal government is proposing new rules that aim to bolster ...

July 23, 2024 — Long-acting injectable cabotegravir (CAB-LA) was safe and well tolerated as HIV pre-exposure prophylaxis (PrEP ... the development of new drugs to treat the disease, which ...

Harmony Garges, M.D, senior vice president, chief medical officer and head of global medical at ViiV Healthcare, highlighted ...

Indigenous communities in Latin America say they are being excluded from the global HIV/AIDS response, leaving them without access to life-saving medicines and prevention tools. The U.S. Centers ...

1 The phase 3 PURPOSE 2 trial is assessing lenacapavir as a pre-exposure prophylaxis (PrEP) medicine to reduce the chance of getting HIV through sex, comparing it when taken twice per year as PrEP ...

Human immunodeficiency virus (HIV) is a condition that attacks a person's immune system. The immune system helps identify and destroy pathogens that cause infection and illness in the body. The risk ...